Ashok B Jain

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. pmc Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years
    A Jain
    Departments of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Liver Transpl 7:623-30. 2001
  2. ncbi request reprint Hepatitis C virus and renal failure
    A K B Jain
    Thomas E Starzl Transplantation Institute, Pittsburgh, Pennsylvania 15213, USA
    Transplant Proc 35:416-8. 2003
  3. ncbi request reprint Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection
    Ashok B Jain
    Transplantation Institute, The Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Liver Transpl 8:1007-13. 2002
  4. ncbi request reprint The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients
    Ashok Kumar B Jain
    Department of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Liver Transpl 8:841-5. 2002
  5. ncbi request reprint Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report
    Ashok Kumar B Jain
    Department of Surgery, University of Pennsylvania, Philadelphia, PA, USA
    Liver Transpl 8:838-40. 2002
  6. ncbi request reprint Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients
    A K B Jain
    Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, 3601 Fifth Avenue, Falk Medical Building 4th Floor, Pittsburgh, PA 15213, USA
    Transplant Proc 34:1540-1. 2002
  7. ncbi request reprint Steroid withdrawal under tacrolimus for primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis after liver transplantation and long-term survival
    Ashok Jain
    Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Transplant Proc 34:1524-5. 2002
  8. ncbi request reprint A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C
    Ashok Jain
    Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Liver Transpl 8:40-6. 2002
  9. ncbi request reprint Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: a case report
    Jonathan A Fridell
    Department of Surgery, Indiana University School of Medicine, Indianapolis, USA
    Ther Drug Monit 25:117-9. 2003
  10. ncbi request reprint Conversion from tacrolimus to cyclosporine--a based immunosuppression following liver transplantation
    Cataldo Doria
    Department of Surgery, Division of Transplantation, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Exp Clin Transplant 1:48-55. 2003

Detail Information

Publications10

  1. pmc Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years
    A Jain
    Departments of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Liver Transpl 7:623-30. 2001
    ..05) was the only factor found to be significant between patients who had graft loss versus those who recovered...
  2. ncbi request reprint Hepatitis C virus and renal failure
    A K B Jain
    Thomas E Starzl Transplantation Institute, Pittsburgh, Pennsylvania 15213, USA
    Transplant Proc 35:416-8. 2003
  3. ncbi request reprint Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection
    Ashok B Jain
    Transplantation Institute, The Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Liver Transpl 8:1007-13. 2002
    ..Further pharmacokinetic studies of ribavirin in LTx patients with varying degrees of renal function may allow the development of an algorithm for the safer use of ribavirin in HCV-positive LTx patients...
  4. ncbi request reprint The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients
    Ashok Kumar B Jain
    Department of Surgery, Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Liver Transpl 8:841-5. 2002
    ..Great caution and frequent drug level monitoring are necessary when HAART is introduced or withdrawn in HIV-positive recipients of organ transplants...
  5. ncbi request reprint Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report
    Ashok Kumar B Jain
    Department of Surgery, University of Pennsylvania, Philadelphia, PA, USA
    Liver Transpl 8:838-40. 2002
    ..Increase in trough concentration, peak concentration area under the curve concentration, and prolongation of half-life of sirolimus has been shown in a patient who was on a low dose (one fifth the recommended dose) of nelfinavir...
  6. ncbi request reprint Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients
    A K B Jain
    Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, 3601 Fifth Avenue, Falk Medical Building 4th Floor, Pittsburgh, PA 15213, USA
    Transplant Proc 34:1540-1. 2002
  7. ncbi request reprint Steroid withdrawal under tacrolimus for primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis after liver transplantation and long-term survival
    Ashok Jain
    Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Transplant Proc 34:1524-5. 2002
  8. ncbi request reprint A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C
    Ashok Jain
    Thomas E Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Liver Transpl 8:40-6. 2002
    ..In addition, there was no difference in HAI or fibrosis score between the two groups. Either MMF has no anti-HCV effect or its immunosuppressive properties overwhelm its antiviral effect in the clinical setting...
  9. ncbi request reprint Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: a case report
    Jonathan A Fridell
    Department of Surgery, Indiana University School of Medicine, Indianapolis, USA
    Ther Drug Monit 25:117-9. 2003
    ..It is essential to monitor the blood concentrations of sirolimus and adjust the sirolimus dosage when phenytoin administration begins or ends...
  10. ncbi request reprint Conversion from tacrolimus to cyclosporine--a based immunosuppression following liver transplantation
    Cataldo Doria
    Department of Surgery, Division of Transplantation, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Exp Clin Transplant 1:48-55. 2003
    ..Additionally, re-conversion to Tacrolimus for lack of efficacy of Cyclosporine A did not appear to be associated with a recurrence of the condition that caused the initial switch...